MEREO BIOPHARMA GROUP PLC

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company whose pipeline includes therapeutics developed through animal testing. The company's lead programs, such as alvelestat for alpha-1 antitrypsin deficiency and setrusumab for osteogenesis imperfecta, have progressed through preclinical stages that involve in vivo studies on animal models, a standard industry practice for drug development and regulatory approval. As a research-based pharmaceutical entity, Mereo's business model is intrinsically linked to animal-based research to demonstrate safety and efficacy prior to human trials.

The specific evidence cited for this exclusion originates from Cruelty Free Investors, an organization that screens for companies involved in animal testing. While the provided source materials detail a securities lawsuit and licensing agreements, they do not contain the primary documentation of Mereo's animal testing practices. The absence of direct evidence in the gathered materials indicates a need to consult the underlying Cruelty Free Investors assessment to confirm the specific nature and scale of Mereo's animal exploitation activities.